IN8BIO, Inc.
INAB
查看详细走势图
1.990USD
+0.240+13.71%
收盘 12/24, 13:00（美东）报价延迟15分钟
9.13M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+13.71%
5天
+40.14%
1月
+1.53%
6月
-11.16%
今年开始到现在
-74.21%
1年
-71.72%
查看详细走势图
TradingKey IN8BIO, Inc.股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
IN8BIO, Inc.评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
4
位分析师
买入
评级
49.250
目标均价
+2666.85%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
IN8BIO, Inc.亮点
亮点风险
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
IN8BIO, Inc.新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
IN8BIO, Inc.简介
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
公司代码INAB
公司IN8BIO, Inc.
CEOHo (William T)
网址https://www.in8bio.com
常见问题
IN8BIO, Inc.(INAB)的当前股价是多少？
IN8BIO, Inc.(INAB)的当前股价是 1.990。
IN8BIO, Inc.的股票代码是什么？
IN8BIO, Inc.的股票代码是INAB。
IN8BIO, Inc.股票的52周最高点是多少？
IN8BIO, Inc.股票的52周最高点是12.531。
IN8BIO, Inc.股票的52周最低点是多少？
IN8BIO, Inc.股票的52周最低点是1.170。
IN8BIO, Inc.的市值是多少？
IN8BIO, Inc.的市值是9.13M。
IN8BIO, Inc.的净利润是多少？
IN8BIO, Inc.的净利润为-30.44M。
现在IN8BIO, Inc.(INAB)的股票是买入、持有还是卖出？
根据分析师评级，IN8BIO, Inc.(INAB)的总体评级为买入，目标价格为49.250。
IN8BIO, Inc.(INAB)股票的每股收益（EPS TTM）是多少
IN8BIO, Inc.(INAB)股票的每股收益（EPS TTM）是-5.297。
相关品种
